Khouloud Khalfaoui

Ms. Khouloud Khalfaoui

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2025 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
KKKhouloud Khalfaoui
Khouloud Khalfaoui
MCMariem Chebbi
Mariem Chebbi
OSOussema Souiai
Oussema Souiai
IFIlhem Ben Fraj
Ilhem Ben Fraj
MKMonia Ben Khaled
Monia Ben Khaled
IMImen Moumni
Imen Moumni
Sickle cell disease (SCD) is a monogenic disorder caused by the presence of hemoglobin S (Hb S) and is associated with a wide range of clinical complications, including hemolytic anemia, vaso‐occlusive crises (VOC), and acute chest syndrome (ACS). This variability is largely driven by Hb S polymerisation and abnormal cell adhesion, which promote the release of circulating microvesicles (MVs). MVs are small vesicles (0.1–1.0 μm) released from various cell types in response to oxidative stress, cellular activation, or apoptosis. They possess pro‐coagulant and pro‐inflammatory properties and are increasingly recognised as potential modulators of disease processes. In this study, homozygous SCD patients and healthy controls were recruited to characterise their MVs profiles using flow cytometry and to explore associations with clinical and biological parameters. SCD patients exhibited significantly elevated levels of MVs compared to controls. Notably, red cell–derived MVs (RMVs) and phosphatidylserine‐positive MVs (AMVs) were strongly associated with elevated lactate dehydrogenase (LDH) levels and clinical severity. A negative correlation was observed between fetal hemoglobin (Hb F) and endothelial MVs (EMVs), suggesting a protective role of Hb F against endothelial injury. These findings support the potential of MVs as diagnostic and prognostic biomarkers for identifying SCD patients at higher risk of complications.

1 January 2026 in Human Mutation
Verified
Journal Article
Open access
PDF file
IMImen Moumni
Imen Moumni
KKKhouloud Khalfaoui
Khouloud Khalfaoui
MCMariem Chebbi
Mariem Chebbi
LCLeila Chaouch
Leila Chaouch
HOHouyem Ouragini
Houyem Ouragini
SMSamia Menif
Samia Menif
Introduction: Hemoglobinopathies are the most prevalent recessive disorders worldwide, characterized by wide molecular and clinical heterogeneity. They result from mutations within the alpha‐, beta‐, or delta‐globin gene leading to aberrant expression or protein function. These abnormalities are widely spread throughout the Mediterranean basin. Due to their severity and disabling nature, hemoglobinopathies represent a major public health problem. Mutational screening of abnormal hemoglobins (Hbs) allows the creation of a mutation map, which forms the basis for a potential national prevention program in Tunisia. Methods: A total of 260 Tunisian subjects were investigated using biochemical and molecular analyses to identify defects in the globin genes (HBA, HBB, and HBD). The study is aimed at determining the molecular spectrum of hemoglobinopathies and contributing to the development of a comprehensive Hb mutation map in Tunisia. Results: Twenty‐one β ‐thalassemia mutations and 16 rare Hb variants were reported, affecting the HBA, HBD, and HBB genes. Rare Hb variants were identified and described for the first time among Tunisian patients, including Hb A 2 ‐Babinga (HBD:c.410G>A; delta 136: Gly → Asp, GGT → GAT). Other variants, such as Hb Knossos, Hb Summer Hill, Hb Hope, and Hb Köln, which are uncommon in the Mediterranean region, were also detected. Conclusion: This study provides an updated overview of β ‐thalassemia mutations and rare Hb variants in the Tunisian population. These findings are essential for understanding genetic and clinical diversity, improving the clinical management of hemoglobinopathies, and enhancing public health initiatives.

29 September 2026 in Hematology Reports
Verified
Journal Article
Open access
PDF file
Mohamed JEMAAMohamed JEMAA
Mohamed JEMAA
YLYesmine Lahlaoui
Yesmine Lahlaoui
GKGhofrane Kitar
Ghofrane Kitar
KKKhouloud Khalfaoui
Khouloud Khalfaoui
IMImen Moumni
Imen Moumni
ISInes Safra
Ines Safra
The advent of targeted cancer therapies has revolutionized oncology, yet the off-target effects of these agents on healthy cells remain a significant clinical challenge. Anemia is one of the most frequent and debilitating adverse effects associated with pharmacological kinase inhibitors, often attributed to bone marrow suppression. However, accumulating evidence over the past fifteen years has illuminated an alternative mechanism: the direct induction of eryptosis, the programmed suicidal death of erythrocytes. This review provides a comprehensive analysis of the current state of knowledge regarding the induction of eryptosis by pharmacological modulators of the phosphorylation balance. We first detail the molecular machinery of eryptosis, then systematically evaluate the diverse classes of kinase inhibitors, from first-generation tyrosine kinase inhibitors to novel selective agents, as well as the emerging class of phosphatase inhibitors, examining the evidence for their eryptotic potential and the proposed molecular mechanisms driving this effect. Importantly, the majority of the evidence discussed derives from in vitro studies using erythrocytes from healthy donors, and we explicitly distinguish between experimentally demonstrated eryptosis and its proposed contribution to clinical anemia. Finally, we synthesize the clinical implications, discussing the impact on patient management, the potential for using eryptotic biomarkers as predictive tools for drug-induced anemia, and the broader pathophysiological consequences of chronic, drug-accelerated erythrocyte clearance. By integrating current mechanistic insights with clinical observations, this review underscores the importance of considering the kinase–phosphatase equilibrium as a potential determinant of drug safety and erythrocyte survival, and highlights the need for clinical studies to quantify the contribution of eryptosis to drug-induced anemia.